BIOATLA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
BIOATLA, INC. (BCAB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $1.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-08-13
- BIOATLA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-06-30 was $500.00K.
- BIOATLA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-03-31 was $500.00K.
- BIOATLA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2024-03-31 was $3.60M, a 33.33% increase year-over-year.
- BIOATLA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2023-06-30 was $1.70M, a 41.38% decline year-over-year.
- BIOATLA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $4.30M, a 55.67% decline from fiscal 2024.
- BIOATLA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $9.70M, a 44.78% increase from fiscal 2023.
- BIOATLA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $6.70M, a 2.90% decline from fiscal 2022.
- BIOATLA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $6.90M, a 263.16% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.00M 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $500.00K 10-Q · filed 2026-05-15 | ||||
| 2025-12-31 | $4.30M 10-K · filed 2026-03-31 | ||||
| 2024-12-31 | $9.70M 10-K · filed 2026-03-31 | ||||
| 2024-03-31 | $3.60M 10-Q · filed 2024-05-14 | ||||
| 2023-12-31 | $6.70M 10-K · filed 2025-03-28 | ||||
| 2023-06-30 | $1.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $4.40M 10-Q · filed 2023-08-01 | $5.90M derived: sum of 3 quarters · filed 2024-03-26 | $7.50M derived: sum of 4 quarters · filed 2024-03-26 | |
| 2023-03-31 | $2.70M 10-Q · filed 2023-05-11 | $4.20M derived: sum of 2 quarters · filed 2024-03-26 | $5.80M derived: sum of 3 quarters · filed 2024-03-26 | $8.70M derived: sum of 4 quarters · filed 2024-03-26 | |
| 2022-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $3.10M derived: sum of 2 quarters · filed 2024-03-26 | $6.00M derived: sum of 3 quarters · filed 2024-03-26 | $6.90M 10-K · filed 2024-03-26 | $6.90K 10-K · filed 2023-03-23 |
| 2022-09-30 | $1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $4.50M derived: sum of 2 quarters · filed 2022-11-04 | $5.40M 10-Q · filed 2022-11-04 | ||
| 2022-06-30 | $2.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $3.80M 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $900.00K 10-Q · filed 2022-05-05 | ||||
| 2021-12-31 | $1.90M 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |